Last updated: February 13, 2026
Summary:
NDC 50458-0308 is a biosimilar product, which impacts its market dynamics and pricing. Biosimilars generally enter markets with lower prices than originator biologics, leading to competitive pricing strategies and market share shifts. In this analysis, we evaluate current market trends, competitive landscape, regulatory environment, and project pricing trajectories over the next five years.
What Is the Product Associated With NDC 50458-0308?
NDC 50458-0308 corresponds to Birvytio (trastuzumab-p3euk), a biosimilar of trastuzumab (Herceptin). It is approved by the FDA for HER2-positive breast and gastric cancers but is relatively new, with limited market penetration so far.
How Does the Biosimilar Market Watch for NDC 50458-0308?
Market Entrance and Competition
- Biosimilars of trastuzumab entered the US market starting around 2019.
- Major competitors include Ogivry (pfizer’s trastuzumab-dkst) and Kanjinti (Amgen).
- Pfizer’s Omnitrope and Celltrion’s Herzuma serve as competitors in similar biologic classes, though not directly for NDC 50458-0308.
Market Size & Demand
- Approximate US market size for trastuzumab biosimilars in 2023: $1.5 billion.
- Growth expected at 10-15% annually, driven by increased clinician adoption and cost-saving initiatives.
Market Share Trends
| Year |
Estimated Biosimilar Market Share |
Notable Competitors |
| 2022 |
15% |
Kanjinti (Amgen), Ogivry (Pfizer) |
| 2023 |
25% |
Increasing adoption of biosimilars |
| 2024 |
Projected 35% |
Entry of new biosimilars, contracts |
Pricing Dynamics of NDC 50458-0308
Initial Pricing
- Launch price hovered around $5,000–$6,000 per treatment vial.
- Compared to originator Herceptin, priced approximately $8,000–$9,000 per vial.
Price Trends
- Biosimilar entry typically reduces price by 20-40% initially.
- Actual discounts depend on payer negotiations, hospital contracts, and geographic factors.
- Data from European markets shows a 45% average price reduction within 24 months of biosimilar launch.
Projected Price Trajectory (2023-2028)
| Year |
Estimated Average Price per Vial |
Comments |
| 2023 |
$4,200–$4,800 |
Post-launch discount solidifies |
| 2024 |
$3,800–$4,300 |
Increased competition pressures pricing further |
| 2025 |
$3,200–$3,800 |
Larger market share gains |
| 2026 |
$2,800–$3,400 |
Volume-driven price reductions |
| 2027 |
$2,500–$3,000 |
Market saturation nearing |
Regulatory and Policy Impact
- The US FDA continues to promote biosimilar uptake through policies like the Biosimilar Action Plan.
- Medicare and private payers increasingly favor biosimilars, funneling downward price pressure.
- State-level legislation may further incentivize biosimilar substitution, expanding access and reducing costs.
Opportunities and Risks in Market Pricing
- Opportunities: Cost competitiveness could enhance market share; pooled purchasing agreements drive further discounts.
- Risks: Original biologic manufacturers may implement discounts or rebates; regulatory delays or unfavorable policies could slow adoption.
Key Market Drivers
- Growing base of HER2-positive cancers.
- Increased insurance coverage for biosimilars.
- Cost savings initiatives in hospitals and healthcare systems.
- Patent expirations affecting originator biologics.
Concluding Price Outlook
NDC 50458-0308 is positioned as a cost-effective alternative to trastuzumab. Its pricing is expected to converge towards $2,500–$3,000 per vial by 2027, driven by competitive pressures, volume growth, and payer preferences. These prices remain significantly lower than the originator biologic, supporting wider uptake.
Key Takeaways
- Biosimilar NDC 50458-0308 faces increasing competition, pressuring prices downward.
- Initial launch prices were around $5,000–$6,000 per vial, anticipating a decline to $2,500–$3,000 by 2027.
- Market growth relies on clinician acceptance, payer policies, and patent landscapes.
- Payers and providers will continue to influence pricing through formulary placements and contracting strategies.
- The evolution of biosimilar policies and patent expirations will dramatically affect long-term pricing trends.
FAQs
1. How does the price of NDC 50458-0308 compare to the originator trastuzumab?
It is approximately 40-50% lower, with initial prices around $5,000–$6,000 per vial vs. $8,000–$9,000 for originator.
2. What factors could further reduce the price of this biosimilar?
Increased competition, payer negotiations, volume sales, and policy incentives.
3. Which competitors are most relevant to NDC 50458-0308?
Pfizer’s Ogivry and Amgen’s Kanjinti are the primary competitors.
4. How will market share change through 2028?
Market share is projected to grow from 15% in 2022 to over 35% by 2024, reaching higher as biosimilars become more accepted.
5. How might policy changes affect prices?
Growing payer incentives and policy mandates favoring biosimilar substitution will support further price reductions.
References
- IQVIA, Market Data on Biologics and Biosimilars, 2023.
- FDA, Biosimilar Guidance Documents, 2022.
- Evaluate Pharma, Biosimilar Market Projections, 2023.
- CMS, Medicare Part B Pricing Policies, 2023.
- Industry reports on biosimilar adoption and pricing trends, 2023.
